A comparison of etomidate and thiopental anesthesia for cardioversion.
Sixteen ASA class II or III male patients (aged, 52 to 66 years) undergoing elective cardioversion were randomly assigned to receive either thiopental or etomidate according to an observer-blinded, parallel study design. The appropriate drug was administered in 2-mL aliquots every 15 seconds until the patient no longer responded to verbal commands, at which time cardioversion was attempted. The total dose for induction was 0.22 +/- 0.2 mg/kg and 3.2 +/- 0.4 mg/kg for etomidate and thiopental, respectively. The cardiorespiratory data after induction were evaluated for maximal percent change from baseline. The baseline heart rate was 106 +/- 6 beats/min and 98 +/- 8 beats/min for the etomidate and thiopental groups, respectively (mean +/- SEM). The heart rate decreased 5% after induction with etomidate and increased 7% with thiopental (P less than 0.05). The baseline mean arterial pressure (MAP) was 96 +/- 3 mm Hg and 105 +/- 11 mm Hg for the etomidate and thiopental groups, respectively (mean +/- SEM). The MAP decreased 4% with etomidate and 3% with thiopental. Respiratory rate was significantly increased by 22% after etomidate compared with a 22% decrease in respiratory rate with thiopental (P less than 0.05). Seven of eight patients in the thiopental group required only one countershock, whereas four of eight patients in the etomidate group required only one shock. One patient in each group could not be successfully cardioverted. Recovery time and clinical side effects were similar between groups except for mild myoclonus in the etomidate group. Titration to effect of either etomidate or thiopental provided satisfactory anesthesia for elective cardioversion in hemodynamically stable patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Ford
S R
SR
Department of Anesthesia, Stanford University School of Medicine, CA.
Maze
M
M
Gaba
D M
DM
D000368:Aged; D000771:Anesthesia, Intravenous; D001145:Arrhythmias, Cardiac / Q000453:epidemiology / Q000628:therapy*; D001281:Atrial Fibrillation / Q000453:epidemiology / Q000628:therapy; D001282:Atrial Flutter / Q000453:epidemiology / Q000628:therapy; D004554:Electric Countershock; D005045:Etomidate; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013874:Thiopental
D013874:Thiopental; D005045:Etomidate